v3.25.3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Cash flows from operating activities:    
Net loss $ (3,465,626) $ (2,968,271)
Stock-based compensation expense included in -    
Research and development costs
General and administrative costs 1,144,348 340,445
Common stock issued for services 44,711
Unrealized gain (loss) on digital assets 182,887
(Increase) decrease in -    
Advances on research and development contract services 78,016
Prepaid insurance (8,592) 35
Other prepaid expenses 23,814 (24,256)
Increase (decrease) in -    
Accounts payable and accrued expenses 95,661 (90,827)
Research and development contract liabilities 77 98,997
Net cash used in operating activities (1,982,720) (2,565,861)
Cash flows from investing activities:    
Purchase of digital assets (2,637,360)
Net cash used in investing activities (2,637,360)
Cash flows from financing activities:    
Proceeds from sale of securities in registered direct offerings, net of offering costs 2,245,040
Proceeds from sale of securities in registered private placement, net of offering costs 4,178,162
Exercise of common stock warrants 45,800
Net cash provided by financing activities 6,469,002
Cash:    
Net increase (decrease) 1,848,922 (2,565,861)
Balance at beginning of period 1,038,952 4,203,488
Balance at end of period 2,887,874 1,637,627
Supplemental disclosures of cash flow information:    
Interest 5,402 12,389
Income taxes
Non-cash investing and financing activities:    
Settlement of accrued compensation to members of the Board of Directors by issuance of stock options 27,500
Exercise of placement agent warrants on a cashless basis 22
Exercise of pre-funded warrants 242
Conversion of Series A Convertible Preferred Stock into common stock 3,500,000
Accrual of Series B Convertible Preferred Stock 8% cumulative dividend 50,367
Accrual of deferred offering costs $ 6,928

Source

HTML PDF
ZIP